Cargando…
Pharmaceutical market access in developed markets /
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Turin :
SEEd Medical Publishers,
2018.
|
| Temas: | |
| Acceso en línea: | Texto completo |
Tabla de Contenidos:
- Cover; Colophon; Preface; 1. Introduction to the Market Access; 1.1 Origin of the Market Access Term; 1.2 Healthcare Market Access Definition; 1.3 Market Access Key Concepts; 1.4 Cultural Specificities of Market Access; 1.5 Market Access from Payersâ#x80;#x99; Perspective; 1.6 Market Access Agreements; 1.7 Market Access for Orphan Drugs; 1.8 Early Advice; 1.9 Early Access Programs; 1.10 To Know More; 2. Market Access in Germany; 2.1 General Outlook of Healthcare System and Health Policies; 2.2 Pathways of Market Access (Regulation, Pricing, and Reimbursement).
- 2.3 Mapping and Structure of Decision Makers (Reimbursement/HTA)2.4 Organizations/Physician or Patient Organizations; 2.5 Challenges and Catalyzers for Market Access; 2.6 Key Success Factors for Market Access in Germany; 2.7 Look-out for Near Future; 2.8 Acknowledgements; 2.9 References; 3. Market Access in the UK; 3.1 Introduction; 3.2 General Outlook of Healthcare System and Health Policies; 3.3 Pathways of Market Access; 3.4 Mapping and Structure of Decision Makers; 3.5 Challenges and Catalyzers for Market Access; 3.6 Advances in the Near Future; 3.7 Bibliography.
- 4. Market Access in France4.1 General Outlook of Healthcare System; 4.2 Pathways of Market Access (Regulation,  Pricing and Reimbursement); 4.3 Mapping and Structure of Decision Makers; 4.4 Challenges and Catalyzers for Market Access in France; 4.5 Acknowledgements; 4.6 References; 5. Market Access in Italy; 5.1 General Outlook of National Health Service and Health Policies; 5.2 Pathways of Market Access; 5.3 Mapping and Structure of Decision Makers; 5.4 Challenges and Catalyzers for Market Access; 5.5 References; 6. Market Access in Spain.
- 6.1 General Outlook of Healthcare System and Health Policies6.2 Pricing and Reimbursement; 6.3 Mapping and Structure of Decision Makers (Reimbursement/HTA); 6.4 Challenges and Catalyzers for Market Access; 6.5 Innovative Mechanisms for Funding, Purchasing and Paying for Drugs; 6.6 Look-out for Near Future; 6.7 Bibliography; 7. Market Access in Portugal; 7.1 Introduction; 7.2 Healthcare System and Subsystems in Portugal; 7.3 Pathways to Market Access; 7.4 Mapping of Stakeholders; 7.5 Major hurdles; 7.6 References.
- 8. Pharmaceutical Market Access in Denmark, Sweden, and The Netherlands: an Overview8.1 Denmark; 8.2 Sweden; 8.3 The Netherlands; 8.4 References; 9. Market Access in Japan; 9.1 Market Background; 9.2 General Outlook of Healthcare System and Health Policies; 9.3 Structure of Decision Making and Pathways of Market Access; 9.4 Challenges; 9.5 Look-out for Near Future; 9.6 Bibliography; 10. Market Access in Australia; 10.1 Background; 10.2 The Healthcare System; 10.3 Medicare; 10.4 Pathways of Market Access (Regulation, Pricing, and Reimbursement); 10.5 Mapping and Structure of Decision Makers.